An interactive look at pharma, medtech and diagnostics deals made during December 2024. Data courtesy of Biomedtracker.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
An interactive look at pharma, medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
